PMID- 35966098
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220826
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - The role of interleukin-1beta in type 2 diabetes mellitus: A systematic review and 
      meta-analysis.
PG  - 901616
LID - 10.3389/fendo.2022.901616 [doi]
LID - 901616
AB  - Type 2 diabetes mellitus (T2DM) is a multifactorial non-communicable disease that 
      is characterized by insulin resistance and chronic sub-clinical inflammation. 
      Among the emerging inflammatory markers observed to be associated with beta-cell 
      damage is interleukin 1beta (IL1beta), a proinflammatory cytokine that modulates 
      important metabolic processes including insulin secretion and beta-cell apoptosis. 
      The present systematic review and meta-analysis gathers available evidence on the 
      emerging role of IL1beta in T2DM. PubMed and Embase were searched for human studies 
      that assessed 1L1beta in T2DM individuals from 2016-2021. Thirteen studies (N=2680; 
      T2DM=1182, controls=1498) out of 523 were included in the systematic review and 
      only 3 studies in the meta-analysis. Assays were the most commonly used 
      quantification method and lipopolysaccharides as the most common stimulator for 
      IL1beta upregulation. Random and fixed effects meta-analysis showed non-significant 
      mean differences of IL1beta concentrations between the T2DM and controls. Given the 
      high heterogeneity and small subset of studies included, caution is advised in 
      the interpretation of results. The present systematic review and meta-analysis 
      highlights the limited evidence available that could implicate 1L1beta as a potent 
      biomarker for T2DM. Standardization of 1L1beta assays with larger sample sizes are 
      encouraged in future observational and prospective studies.
CI  - Copyright (c) 2022 Alfadul, Sabico and Al-Daghri.
FAU - Alfadul, Hend
AU  - Alfadul H
AD  - Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of 
      Science, King Saud University, Riyadh, Saudi Arabia.
AD  - Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi 
      Arabia.
FAU - Sabico, Shaun
AU  - Sabico S
AD  - Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of 
      Science, King Saud University, Riyadh, Saudi Arabia.
FAU - Al-Daghri, Nasser M
AU  - Al-Daghri NM
AD  - Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of 
      Science, King Saud University, Riyadh, Saudi Arabia.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220727
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers)
RN  - 0 (IL1B protein, human)
RN  - 0 (Interleukin-1beta)
SB  - IM
MH  - Biomarkers
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - *Insulin Resistance
MH  - Interleukin-1beta/*metabolism
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC9363617
OTO - NOTNLM
OT  - cytokines
OT  - inflammasome
OT  - inflammation
OT  - inflammatory disease
OT  - interleukin 1beta
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/01/01
CRDT- 2022/08/15 03:34
PHST- 2022/03/22 00:00 [received]
PHST- 2022/07/04 00:00 [accepted]
PHST- 2022/08/15 03:34 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.901616 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Jul 27;13:901616. doi: 
      10.3389/fendo.2022.901616. eCollection 2022.